Pliant Therapeutics Q3 EPS $(0.70) Beats $(0.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics (NASDAQ:PLRX) reported Q3 losses of $(0.70) per share, beating the analyst consensus estimate of $(0.77) by 9.09%. However, this is a 7.69% increase in losses compared to the same period last year.
November 09, 2023 | 10:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pliant Therapeutics reported better than expected Q3 losses, but the losses increased compared to last year.
While Pliant Therapeutics beat the analyst consensus estimate, the increase in losses compared to the same period last year could potentially offset any positive sentiment. The impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100